Results 121 to 130 of about 40,704 (273)

Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease

ARYA Atherosclerosis, 2011
BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD).
Arash Akhlaghi, Shahin Shirani, Naghmeh Ziaie, Omid Pirhaji, Majid Yaran, Golnoosh Shahverdi, Nizal Sarrafzadegan, Alireza khosravi, Elham khosravi   +8 more
doaj  

CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. [PDF]

PLoS ONE, 2013
Several studies have indicated that CYP2C19 loss-of-function polymorphisms have a higher risk of stent thrombosis (ST) after percutaneous coronary interventions (PCIs).
Xiang Xie, Yi-Tong Ma, Yi-Ning Yang, Xiao-Mei Li, Xiang Ma, Zhen-Yan Fu, Ying-Ying Zheng, Bang-Dang Chen, Fen Liu   +8 more
doaj   +1 more source

Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account

Clinical Pharmacology &Therapeutics, EarlyView.
The polymorphic CYP2D6 enzyme plays a pivotal role in the metabolism of approximately 25% of clinically prescribed drugs. However, the impact of specific genetic variants on the interindividual variability in CYP2D6‐mediated drug metabolism remains insufficiently quantified. This translational study sought to address this gap by analyzing the genotypes
Inger Johansson, Emmanouella M. Xanthopoulou, Yitian Zhou, Anabel Sanchez‐Spitman, Maaike van der Lee, Birgit M. Wollmann, Elisabet Størset, Jesse J. Swen, Henk‐Jan Guchelaar, Espen Molden, Marin M. Jukic, Magnus Ingelman‐Sundberg   +11 more
wiley   +1 more source

Genetic Polymorphism of CYP2C19 in Pakistani Population.

Iranian journal of pharmaceutical research : IJPR, 2019
CYP2C19 polymorphism is associated with pretreatment drug response prediction, metabolism, and disposition. Pakistan consists of a population comprising of various ethnic groups residing in different regions of the country each claiming diverse ethnic origins.
Yusra Latif, Sadia Muhammad Din, Muhammad Usman Tareen, Saima Siddiqi, Sana Riaz, Aneesa Sultan, Fizza Tariq, Atika Mansoor   +7 more
openaire   +3 more sources

Clinical applications of pharmacogenomics [PDF]

, 2017
Indexación: Scopus.Pharmacogenomics is an emergent field aimed at tailoring pharmacological therapy. Genetic polymorphisms can modify the expression and function of enzymes and proteins involved in drug metabolism, affecting absorption, distribution ...
Cayún, J.P., Escalante, P., Gallegos, B., Lares-Asseff, I., Meneses, F., Miranda, C., Quiñones, L., Roco, Á., Varela, N., Zaruma-Torres, F.   +9 more
core   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

ASSESSMENT OF THE CLOPIDOGREL ACTION WITH REGARD TO CYP2C19 GENE POLYMORPHISMS IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER IMPLANTATION OF DES STENTS

Евразийский Кардиологический Журнал, 2019
Aim of the work to assess the impact of CYP2C19 polymorphisms, including those of CYP2C19*1, CYP2C19*2, CYP2C19*3 and CYP2C19*17 on clopidogrel response variability in patients undergoing percutaneous coronary intervention (PCI) following DES ...
J. K. Uzokov, B. A. Alyavi, A. X. Abdullaev   +2 more
doaj  

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

Clinical pharmacology and therapy, 2023
C. Bousman, J. Stevenson, L. Ramsey, K. Sangkuhl, J. K. Hicks, J. Strawn, Ajeet B. Singh, G. Ruaño, D. J. Mueller, Evangelia Eirini Tsermpini, Jacob T Brown, G. Bell, J. Leeder, A. Gaedigk, Stuart A. Scott, T. Klein, K. Caudle, J. Bishop   +17 more
semanticscholar   +1 more source

Estimating the Frequency of False‐Negative Pharmacogenetic Test Results by Self‐Reported Ancestry

Clinical Pharmacology &Therapeutics, EarlyView.
Concerns about the applicability of pharmacogenetic (PGx) testing across diverse ancestry groups have risen from the underrepresentation of non‐European populations in PGx research. Current PGx panels may fail to detect relevant variants in non‐European populations, increasing the likelihood of false‐negative results.
Weng‐Sam Siu, Abdullah Al Maruf, Sarker M. Shaheen, Ryden McCloud, Madison Heintz, Laina McAusland, Paul D. Arnold, Chad A. Bousman   +7 more
wiley   +1 more source

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing

Clinical Pharmacology &Therapeutics, EarlyView.
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Ashley N. Springer, Leah A. Alicea, Yemi Gafari, Tayler B. Smith, Sheryl Lynch, Amy M. Breman, Jennelle C. Hodge, Victoria M. Pratt, Nicholas R. Powell, Rolf P. Kreutz, Daniel P. Kobold, Michael T. Eadon, Emma M. Tillman, Tyler Shugg, Todd C. Skaar   +14 more
wiley   +1 more source